Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence?
Article first published online: 25 JAN 2006
Annals of the New York Academy of Sciences
Volume 949, SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs) pages 215–222, December 2001
How to Cite
YAFFE, K. (2001), Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence?. Annals of the New York Academy of Sciences, 949: 215–222. doi: 10.1111/j.1749-6632.2001.tb04024.x
- Issue published online: 25 JAN 2006
- Article first published online: 25 JAN 2006
- selective estrogen receptor modulators;
Abstract: At least 10% of people aged 65 or older have some form of cognitive impairment, increasing to around 50% by age 85. Several studies have suggested that estrogen may improve cognitive function or prevent the development of dementia, but other studies have not shown a benefit, and results from large randomized trials are lacking. Fortunately, further trials are currently being conducted. With the recognition that selective estrogen receptor modulators (SERMs) have differential tissue-dependent effects on estrogen receptor function, there is recent interest in the effects of raloxifene, tamoxifen, and other SERMs on cognition. In this paper, the current state of knowledge of the role of estrogen for preventing dementia in postmenopausal women will be reviewed. In addition, the status of ongoing and recently completed trials of estrogen and SERMs on cognitive function or on Alzheimer's disease severity will be summarized.